Research.
Longieva Therapeutics is leveraging 20 years of experience developing therapeutics targeting GPCRs for brain disorders. We are making significant progress in engineering safe and effective ligands for these receptors.
Our most advanced candidate has entered preclinical IND-enabling studies. We project IND submission and initiation of the Phase I trial by Q4 2025.
Broad Potential With Biased Small Molecule GPCR Agonists
